Trial Profile
A Prospective-Cohort Study Assessing the Safety of Conversion from CNI-to-Belatacept Based Immunosuppression using Urinary CXCL9 Monitoring in Kidney Transplant Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jul 2018
Price :
$35
*
At a glance
- Drugs Belatacept (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions
- 13 Jul 2018 New trial record
- 06 Jun 2018 Results presented at the 2018 American Transplant Congress.